MEET OUR TEAM
Our experienced team has carved a path over decades of academic and industry roles. We are motivated to confront unmet medical needs in the world with novel and compelling science.
Meet The Onchilles Team
- Headshot of Court R. Turner, JDCourt R. Turner, JDCo-founder and Chief Executive Officer
- Headshot of Lev Becker, PhDLev Becker, PhDCo-founder
- Headshot of Marc Nasoff, PhDMarc Nasoff, PhDChief Development Officer
- Headshot of Emily Roberts-ThomsonEmily Roberts-ThomsonSVP, Development Operations
- Headshot of Peter Haberz, PhDPeter Haberz, PhDVice President, Corporate Development
- Headshot of Chang Cui, PhDChang Cui, PhDSenior Scientist
- Headshot of Ravindra Gujar, PhDRavindra Gujar, PhDSenior Scientist
- Headshot of Carmen WhiteCarmen WhiteSenior Accountant
- Headshot of Maria FumagalliMaria FumagalliSenior Research Associate
- Headshot of Nicole MartinezNicole MartinezResearch Associate
Meet Our Board Of Directors
- Headshot of Kevin Li, PhDKevin Li, PhDLYZZ Capital
- Headshot of Mike Liang, PhDMike Liang, PhDInVivium Capital
- Headshot of Maarek MascarenhasMaarek MascarenhasKennedy Lewis Investment Management
- Headshot of Court R. Turner, JDCourt R. Turner, JDChair
- Headshot of Lev Becker, PhDLev Becker, PhD
Key Advisors
- Headshot of Alain Algazi, MDAlain Algazi, MDClinical Advisor
- Headshot of Igor Puzanov, MD, MSCI, FACPIgor Puzanov, MD, MSCI, FACPClinical Advisor
- Headshot of Thomas Buchholz, M.D.Thomas Buchholz, M.D.Clinical Advisor
- Headshot of Hajime Hiraragi, DVM, DABTHajime Hiraragi, DVM, DABTToxicology Advisor
DISCOVER YOUR PATH
Onchilles Pharma is looking for talented and enthusiastic people to join our quest.
LATEST NEWS
Keep up to date with all the latest news from Onchilles Pharma
Onchilles Pharma to Present OP-NEU-101 Trial in Progress at ESMO Congress 2026
N17350 is designed to leverage the ELANE pathway, a cancer-selective mechanism that induces immunogenic cancer cell death while sparing healthy tissue, including immune cells. In preclinical studies, N17350 demonstrated broad tumor-killing activity, immune cell preservation, and activation of anti-tumor immunity across multiple solid tumor models.
Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid Tumors
N17350 is designed to leverage the ELANE pathway, a cancer-selective mechanism that induces immunogenic cancer cell death while sparing healthy tissue, including immune cells. In preclinical studies, N17350 demonstrated broad tumor-killing activity, immune cell preservation, and activation of anti-tumor immunity across multiple solid tumor models.
Subscribe To Our Newsletter
Keep up to date with all the latest news from Onchilles Pharma